HDFC Pharma and Healthcare Fund Direct Growth
EquitySector - HealthcareVery High Risk
Direct
NAV (19-Sep-24)
Returns (Since Inception)
Fund Overview
Fund Size
₹1,170 Cr
Expense Ratio
0.98%
ISIN
INF179KC1HO1
Minimum SIP
₹100
Exit Load
1.00%
Inception Date
04 Oct 2023
About this fund
As of 19-Sep-24, it has a Net Asset Value (NAV) of ₹16.16, Assets Under Management (AUM) of 1169.59 Crores, and an expense ratio of 0.98%.
- HDFC Pharma and Healthcare Fund Direct Growth has given a CAGR return of 62.13% since inception.
- The fund's asset allocation comprises around 97.74% in equities, 0.00% in debts, and 2.26% in cash & cash equivalents.
- You can start investing in HDFC Pharma and Healthcare Fund Direct Growth with a SIP of ₹100 or a Lumpsum investment of ₹100.
Performance against Category Average
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
Since Inception
+62.13%
— (Cat Avg.)
Portfolio Summaryas of 31st August 2024
| Equity | ₹1,143.14 Cr | 97.74% |
| Others | ₹26.44 Cr | 2.26% |
Top Holdings
All Holdings
Equity
Debt & Others
| Name | Type  | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹136.06 Cr | 11.63% |
| Divi's Laboratories Ltd | Equity | ₹88.36 Cr | 7.55% |
| Cipla Ltd | Equity | ₹64.81 Cr | 5.54% |
| Dr Reddy's Laboratories Ltd | Equity | ₹63.28 Cr | 5.41% |
| Lupin Ltd | Equity | ₹55.9 Cr | 4.78% |
| Aurobindo Pharma Ltd | Equity | ₹53.47 Cr | 4.57% |
| Ajanta Pharma Ltd | Equity | ₹45.74 Cr | 3.91% |
| Gland Pharma Ltd | Equity | ₹43.92 Cr | 3.75% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹41.78 Cr | 3.57% |
| Ipca Laboratories Ltd | Equity | ₹38.96 Cr | 3.33% |
| Zydus Lifesciences Ltd | Equity | ₹37.82 Cr | 3.23% |
| Eris Lifesciences Ltd Registered Shs | Equity | ₹36.26 Cr | 3.10% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹36.02 Cr | 3.08% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹34.1 Cr | 2.92% |
| Piramal Pharma Ltd | Equity | ₹33.16 Cr | 2.84% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹31.4 Cr | 2.68% |
| Treps - Tri-Party Repo | Cash - Repurchase Agreement | ₹30.22 Cr | 2.58% |
| Fortis Healthcare Ltd | Equity | ₹29.32 Cr | 2.51% |
| Pfizer Ltd | Equity | ₹28.12 Cr | 2.40% |
| Thyrocare Technologies Ltd | Equity | ₹27.76 Cr | 2.37% |
| Torrent Pharmaceuticals Ltd | Equity | ₹26.39 Cr | 2.26% |
| Metropolis Healthcare Ltd | Equity | ₹25.89 Cr | 2.21% |
| Wockhardt Ltd | Equity | ₹24.39 Cr | 2.08% |
| Jubilant Pharmova Ltd | Equity | ₹20.78 Cr | 1.78% |
| Alkem Laboratories Ltd | Equity | ₹20.42 Cr | 1.75% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹19.97 Cr | 1.71% |
| Suven Pharmaceuticals Ltd | Equity | ₹19.96 Cr | 1.71% |
| Ami Organics Ltd | Equity | ₹17.83 Cr | 1.52% |
| Emcure Pharmaceuticals Ltd | Equity | ₹13.99 Cr | 1.20% |
| Medplus Health Services Ltd | Equity | ₹9.29 Cr | 0.79% |
| Dr. Lal PathLabs Ltd | Equity | ₹9.22 Cr | 0.79% |
| Unichem Laboratories Ltd | Equity | ₹8.8 Cr | 0.75% |
| Net Current Assets | Cash | ₹-3.78 Cr | 0.32% |
Allocation By Market Cap (Equity)
Large Cap Stocks
32.40%
Mid Cap Stocks
32.46%
Small Cap Stocks
31.69%
Other Allocation
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹1,125.32 Cr | 96.22% |
| Basic Materials | ₹17.83 Cr | 1.52% |
Risk & Performance Ratios
Standard Deviation
This fund
--
Cat. avg.
15.96%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.79
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.44
Higher the better
Fund Managers
Dhruv Muchhal
Since October 2023
Nikhil Mathur
Since October 2023
Additional Scheme Detailsas of 31st August 2024
ISIN | INF179KC1HO1 | Expense Ratio | 0.98% | Exit Load | 1.00% | Fund Size | ₹1,170 Cr | Age | 04 Oct 2023 | Lumpsum Minimum | ₹100 | Fund Status | Open Ended Investment Company | Benchmark | BSE Healthcare TR INR |
Investment Objective
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Tax Treatment
Capital Gains Taxation:
- If units are sold after 1 year from the date of investment: Gains up to INR 1.25 lakh in a financial year are exempt from tax. Any gains exceeding INR 1.25 lakh are taxed at a rate of 12.5%.
- If units are sold within 1 year from the date of investment: The entire amount of gain is taxed at a rate of 20%.
- Holding the units: No tax is applicable as long as you continue to hold the units.
Dividend Taxation:
Dividends are added to the investor’s income and taxed according to their respective tax slabs. Additionally, if an investors dividend income exceeds INR 5,000 in a financial year, the fund house deducts a 10% Tax Deducted at Source (TDS) before distributing the dividend.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Similar Sector - Healthcare Funds
| Fund name | Expense Ratio | Exit Load | Fund size | 1Y  |
|---|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹17.49 Cr | 53.5% |
| Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 0.9% | 1.0% | ₹862.61 Cr | 52.3% |
| Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹862.61 Cr | 50.2% |
| Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹37.00 Cr | 50.2% |
| ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹194.84 Cr | 54.0% |
| ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹194.84 Cr | 51.1% |
| Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2758.76 Cr | 50.9% |
| Mirae Asset Healthcare Fund Regular Growth Very High Risk | 1.9% | 1.0% | ₹2758.76 Cr | 48.6% |
| Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹798.61 Cr | 48.5% |
| Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹19.93 Cr | 49.1% |
About the AMC
Total AUM
₹7,06,808 Cr
Address
“HUL House”, 2nd Floor, Mumbai, 400 020
Other Funds by HDFC Mutual Fund
Risk Level
Your principal amount will be at Very High Risk
Unlock Expert Insights!
Related Articles
Still got questions?
We're here to help.
What is the current NAV of HDFC Pharma and Healthcare Fund Direct Growth?
What is the portfolio composition of HDFC Pharma and Healthcare Fund Direct Growth?
Who manages the HDFC Pharma and Healthcare Fund Direct Growth?
- Dhruv Muchhal
- Nikhil Mathur
Dezerv Investments Private Limited is a Portfolio Manager with SEBI Registration no. INP000007377 and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.
Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.